GMAB Earnings
Genmab A/S
$
22.670
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Genmab A/S(GMAB) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Genmab A/S earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: DKK
Actual
Estimate
Surprise Analysis
| FY2025Q2 | 2025-08-07 | Pre-Market | 0.39 | - | - | 901.20M | 926.54M | +2.81 | +5.49 | +1.67 |
| FY2025Q1 | 2025-05-08 | Pre-Market | 0.23 | - | - | 5.02B | 4.73B | -5.73 | -5.73 | -6.26 |
| FY2024Q4 | 2025-02-12 | Pre-Market | 0.36 | - | - | 6.39B | 6.44B | +0.79 | +4.24 | +16.30 |
| FY2024Q1 | 2024-05-02 | - | 0.16 | 0.16 | - | 3.99B | 4.14B | +3.86 | -3.58 | +0.17 |
| FY2023Q4 | 2024-02-14 | - | 0.34 | 0.36 | +5.88 | 4.61B | 4.68B | +1.48 | +4.39 | +9.53 |
| FY2023Q3 | 2023-11-07 | - | 0.34 | 0.47 | +38.24 | 4.47B | 4.74B | +6.03 | +2.32 | +11.44 |
| FY2023Q2 | 2023-08-03 | - | 0.31 | 0.30 | -3.23 | 4.07B | 4.20B | +3.13 | -0.76 | -4.50 |
| - | 2023-05-10 | - | 0.09 | 0.05 | -44.44 | - | - | - | +1.95 | +4.98 |
| - | 2023-02-22 | - | 0.35 | 0.12 | -65.71 | - | - | - | -3.26 | -4.33 |
| - | 2022-11-09 | - | 0.23 | 0.53 | +130.43 | - | - | - | +3.12 | +7.67 |
GMAB Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Genmab A/S reported performance for FY2025Q2, announced on 2025-08-07. The company achieved an EPS of , compared to analyst estimates of 0.39 by % . Revenue for the quarter reached 926.54M compared to expectations of 901.20M by 2.81% .
The stock price reacted with a 5.49% one-day change and a 1.67% five-day change following the earnings release. These movements reflect market reaction in Genmab A/S growth trajectory and strategic initiatives.
GMAB Earnings Forecast
Looking ahead, Genmab A/S(GMAB) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 964.71M and an EPS of 0.44.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -1.97%, while EPS estimates have been Revise Upward by 3.55%. For the upcoming Q3 2025, revenue estimates have been adjusted Revise Upward by 0.9% . These revisions correlate with a 18.82% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Genmab A/S long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between GMAB's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Downward
-1.97%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+3.55%
In Past 3 Month
Revenue Estimates for Q3 2025
Revise Upward
+0.9%
In Past 3 Month
Stock Price
Go Up
+18.82%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:3.57B
--
EPS Estimate-Annual FY 2025:15.84
—
Stock Price22.67
GMAB Revenue and EPS Performance: A Historical Perspective
Genmab A/S revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-08-07,Pre-Market):
EPS: (Actual) vs.0.39 (Estimate) (%)
Revenue: 926.54M (Actual) vs. 901.20M (Estimate) (2.81%)
Price Reaction: 5.49%(1-Day), 1.67%(5-Day)
FY2025Q1 (2025-05-08,Pre-Market):
EPS: (Actual) vs.0.23 (Estimate) (%)
Revenue: 4.73B (Actual) vs. 5.02B (Estimate) (-5.73%)
Price Reaction: -5.73%(1-Day), -6.26%(5-Day)
FY2024Q4 (2025-02-12,Pre-Market):
EPS: (Actual) vs.0.36 (Estimate) (%)
Revenue: 6.44B (Actual) vs. 6.39B (Estimate) (0.79%)
Price Reaction: 4.24%(1-Day), 16.30%(5-Day)
Earnings Reaction
The chart below shows how GMAB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, GMAB sees a +1.82% change in stock price 10 days leading up to the earnings, and a +2.79% change 10 days following the report. On the earnings day itself, the stock moves by +0.82%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed -5.55% on the day following the earnings release and then changed by -0.09% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Genmab A/S (GMAB) Q2 2025 Earnings Call Summary
Positive
2025-08-07
The earnings call summary indicates strong financial performance with significant revenue and profit growth, a robust cash position, and high recurring revenue contribution. The share buyback program further reflects confidence in the company's future. The Q&A section highlights management's confidence in their product pipeline and strategic plans despite some lack of revenue guidance. Overall, the strong financial results and positive outlook on product development contribute to a positive sentiment, likely resulting in a stock price increase of 2% to 8%.
Genmab A/S (GMAB) Q3 2024 Earnings Conference Call Summary
Positive
2024-11-09
Genmab's strong financial performance, with a 29% revenue increase and positive product sales, outweighs concerns about integration and supply chain risks. The optimistic guidance and strategic focus on Phase 3 programs suggest a positive outlook. Despite no shareholder return plan, the market's reaction is likely to be positive, given the strong earnings and optimistic guidance. The Q&A revealed no major negative sentiment, further supporting a positive stock price movement.
Genmab A/S (GMAB) Q2 2024 Earnings Call Summary
Positive
2024-08-12
The earnings call shows strong financial performance with significant revenue and profit growth, and optimistic guidance for 2024. Despite some risks in development and supply chain challenges, the company's strategic initiatives, including regulatory approvals and increased R&D investments, are promising. The Q&A reveals management's confidence in R&D and partnerships, though some uncertainties remain. Overall, the strong financials and strategic growth plans suggest a positive stock price movement.
People Also Watch
EPAM
Epam Systems Inc
160.800
USD
+5.15%
WIX
Wix.Com Ltd
120.730
USD
+2.90%
GLPI
Gaming and Leisure Properties Inc
46.250
USD
+0.83%
VIV
Telefonica Brasil SA
12.170
USD
-0.57%
MRNA
Moderna Inc
26.890
USD
+4.79%
HEI
HEICO Corp
312.930
USD
-0.99%
AMH
American Homes 4 Rent
34.890
USD
+1.87%
CLH
Clean Harbors Inc
250.430
USD
+2.19%
CLS
Celestica Inc
204.220
USD
-4.32%
MBLY
Mobileye Global Inc
14.250
USD
+2.15%
FAQ
What were the key highlights of GMAB’s latest earnings report for FY2025Q2?
GMAB reported its FY2025Q2 earnings on 2025-08-07, showcasing a revenue of 926.54M against an estimate of 901.20M, resulting in a 2.81% surprise. The EPS was 0, surpassing the expected 0.39 by 0% . The stock experienced a 5.49% price change on the earnings day and a 1.67% change over the next five days, reflecting market reactions to the results.
How did GMAB’s stock price react after the FY2025Q2 earnings release?
What are the revenue and EPS estimates for GMAB for 2025/Q3?
How does GMAB’s stock price correlate with earnings forecast revisions?
What should investors expect from GMAB’s next earnings report?